LUMOS PHARMA INC. - COMMON STOCK

Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

20 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency

14 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency

20 Mar 2021 11:00:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in March 2021 Investor Conferences

11 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD

09 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society

04 Mar 2021 09:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting

02 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021

22 Feb 2021 16:15:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces Changes to its Board of Directors

16 Feb 2021 16:01:00 By Nasdaq GlobeNewswire